Tumor Profiling in Melanoma
With our advanced plate of Tumor Profiling to Guide Targeted Cancer Therapy, Creative Biolabs has developed an unparalleled platform for melanoma tumor profiling. To fulfill every need of our consumers, our professional scientists are ready to start working on your projects.
Introduction of Tumor Profiling in Melanoma
Melanoma is characterized by elevated genetic and epigenetic mutational loads that are convenient for tumor metastasis and drug resistance. Understanding the high melanoma heterogeneity is of great meaning for decoding melanoma development and progression. In the area of precision medicine, advances in tumor profiling technology have boosted the demystification process of melanoma heterogeneity. A comprehensive tumor profiling could improve the therapeutic effectiveness and avoid useless effort failure on drug resistance in the melanoma diagnosis, classification, and immunotherapy treatment.
Fig.1 Some key immune checkpoint blockers and predictive biomarkers.1
Tumor Profiling in Melanoma at Creative Biolabs
Recent advances in Technologies for Tumor Profiling have provided us insight into the heterogeneity of melanoma tumor cells. We could provide melanoma tumor Profiling in different biomarker expression levels.
- List of some well-studied melanoma tumor biomarkers
The biological samples could be primary tumor biopsies, cell lines, liquid biopsies, stool, and so on.
- Workflow for melanoma cancer tumor profiling
Features of Tumor Profiling in Melanoma at Creative Biolabs
- Expertise in tumor profiling with professional technologies.
- From top-level design to experimental detail work.
- Extensive project management.
Creative Biolabs has been delicately working in the field of tumor profiling for years, and our scientists are fully confident of completing the most challenging projects in this area. For additional details on our services, please feel free to contact us directly.
Reference
- Puglisi, Rossella, et al. "Biomarkers for diagnosis, prognosis and response to immunotherapy in melanoma." Cancers 13.12 (2021): 2875. Distributed under Open Access license CC BY 4.0, without modification.
Download our brochure